Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

• Hauptverfasser: Wolfgang Koenig (Verfasst von), Kausik K. Ray (Verfasst von), Ulf Landmesser (Verfasst von), Lawrence A. Leiter (Verfasst von), Gregory G. Schwartz (Verfasst von), R. Scott Wright (Verfasst von), Lorena Garcia Conde (Verfasst von), Jackie Han (Verfasst von), Frederick J. Raal (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2023-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Patients with cerebrovascular disease (CeVD) have been shown to benefit from lipid-lowering therapies, but guideline-recommended levels of low-density lipoprotein cholesterol (LDL-C) are often not attained with statin treatment alone. The ORION-9, ORION-10, and ORION-11 trials evaluated the efficacy...